Severe heart failure and intracardiac thrombosis: going beyond the appearance for diagnosis and treatments

Submitted: December 18, 2023
Accepted: March 27, 2024
Published: May 2, 2024
Abstract Views: 569
PDF_EARLY VIEW: 275
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

We describe the case of a 45-year-old female affected by asthma and nasal polyposis who presented to the emergency department because of worsening dyspnea and paresthesia of the left lower limb. Comprehensive instrumental examinations revealed the presence of severe left ventricle dysfunction, intra-cardiac thrombus, deep vein thrombosis, pulmonary embolism, lung infiltrates, polyserositis, and neurological involvements. Finally, the patient was diagnosed with eosinophilic granulomatosis with polyangiitis (EGPA), formerly Churg-Strauss syndrome, a rare vasculitis of small-medium blood vessels with several organ involvements. Treatment with anticoagulants, corticosteroids, and cyclophosphamide led to a significant clinical improvement. However, a subcutaneous cardiac defibrillator was implanted because of the persistence of severe left ventricular dysfunction and the high cardiovascular risk phenotype. Indeed, several cardiac manifestations may occur in EGPA, particularly in patients with anti-neutrophil cytoplasmic antibody-negative disease. Therefore, clinicians should have high clinical suspicion because cardiac involvement in EGPA results in a poor prognosis if not diagnosed and adequately treated.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 1951;27:277-301.
White J, Dubey S. Eosinophilic granulomatosis with polyangiitis: a review. Autoimmun Rev 2023;22:103219. DOI: https://doi.org/10.1016/j.autrev.2022.103219
Grayson PC, Ponte C, Suppiah R, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis 2022;81:309-14. DOI: https://doi.org/10.1136/annrheumdis-2021-221794
Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2022;43:3997-4126. DOI: https://doi.org/10.1093/eurheartj/ehac699
Emmi G, Bettiol A, Gelain E, et al. Evidence-based guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. Nat Rev Rheumatol 2023;19:378-93. DOI: https://doi.org/10.1038/s41584-023-00958-w
Neumann T, Manger B, Schmid M, et al. Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore) 2009;88(4):236-43. DOI: https://doi.org/10.1097/MD.0b013e3181af35a5
Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999;78:26-37. DOI: https://doi.org/10.1097/00005792-199901000-00003
Garcia-Vives E, Rodriguez-Palomares JF, Harty L, et al. Heart disease in eosinophilic granulomatosis with polyangiitis (EGPA) patients: a screening approach proposal. Rheumatology (Oxford) 2021;60:4538-47. DOI: https://doi.org/10.1093/rheumatology/keab027
Maino A, Rossio R, Cugno M, et al. Hypereosinophilic syndrome, Churg-Strauss syndrome and parasitic diseases: possible links between eosinophilia and thrombosis. Curr Vasc Pharmacol 2012;10:670-5. DOI: https://doi.org/10.2174/157016112801784594
Bond M, Fagni F, Moretti M, et al. At the heart of eosinophilic granulomatosis with polyangiitis: into cardiac and vascular involvement. Curr Rheumatol Rep 2022;24:337-51. DOI: https://doi.org/10.1007/s11926-022-01087-1
Jachiet M, Samson M, Cottin V, et al. Anti‐IgE monoclonal antibody (omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg‐Strauss): data on seventeen patients. Arthritis Rheumatol 2016;68:2274-82. DOI: https://doi.org/10.1002/art.39663
Faverio P, Bonaiti G, Bini F, et al. Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy. Ther Clin Risk Manag 2018:2385-96. DOI: https://doi.org/10.2147/TCRM.S159949
Mohammad A, Hot A, Arndt F, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg–Strauss). Ann Rheum Dis 2016;75:396-401. DOI: https://doi.org/10.1136/annrheumdis-2014-206095
Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-14. DOI: https://doi.org/10.1056/NEJMoa025217

How to Cite

Segreti, Andrea, Sara Mastroberardino, Lorenzo Frau, Alessandro Appetecchia, Luca D’Antonio, Danilo Ricciardi, Gian Paolo Ussia, and Francesco Grigioni. 2024. “Severe Heart Failure and Intracardiac Thrombosis: Going Beyond the Appearance for Diagnosis and Treatments”. Monaldi Archives for Chest Disease, May. https://doi.org/10.4081/monaldi.2024.2882.

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.